Head-to-head · WeighScore
GOAL.MD vs Medro
The verdict
GOAL.MD takes it — 68.6/100 to 63.6/100.
GOAL.MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GOAL.MD is a St. Louis-based telehealth platform offering compounded semaglutide alongside brand-name bridges to Ozempic, Wegovy, and Zepbound. Its standout is a manual-renewal model — no auto-billing
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | GOAL.MD | Medro |
|---|---|---|
| WeighScore | 68.6/100 | 63.6/100 |
| Grade | C | C |
| Scorecard rank | #142 | #252 |
| Semaglutide | $179/mo | $199/mo (compounded) |
| Tirzepatide | $249/mo (starting dose, compounded) | $299/mo (compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #142 · C
Strengths
- Transparent dose-tiered pricing on brand pens
- LegitScript Certified
- Manual-renewal model — no surprise auto-billing
- Free nutrition coach included
- BBB A+ rating since 2021
Where it loses points
- No named compounding pharmacy partner
- Co-founder and chief physician has a 2016 federal guilty plea for distributing misbranded HGH and a (reinstated) license revocation
- No URAC or PCAB pharmacy accreditation
Graded #252 · C
Strengths
- Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
- LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
- No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
- Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).
Where it loses points
- Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
- Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
- Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
- Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.